Skip to main content
. 2015 Aug 10;112(34):10786–10791. doi: 10.1073/pnas.1422749112

Fig. S2.

Fig. S2.

In vivo results using mAb3F8 and mAb81.2 dose titration. (A and B) PB leukemic cell frequency (A) and platelet counts (B) at 35 d after transplantation in NOD/SCID mice engrafted with MA9Ras cells and treated with mAb81.2 or mAb3F8 or a corresponding isotype control antibody (means ± SD; n = 3–7 per group). (C) Overall survival rates after treatment with mAb81.2 (median 58 d), mAb3F8 (median 57 d), and control (median 51 d) (P < 0.0001; n = 7 for all groups). P values were calculated by using the Mantel Cox log rank test. (D and E) Leukemic cell frequency in BM (D) and spleen (E) (means ± SD). (F and G) Spleen weight (F) and estimated leukemic spleen burden (G) calculated as frequency of leukemic cells multiplied by spleen weight (means ± SD). Unless otherwise stated, P values were calculated with Student’s t test.